Statement: 2 cases of hematolysis were recorded in the primary trial, none in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 9/157 (5.73%)   Blood disorder 1/157 (0.64%)   Hemoglobin decreased 1/157 (0.64%)   Hemolysis 0/157 (0.00%)   Arrhythmia 0/157 (0.00%)   Cardiac disorder 0/157 (0.00%)   Myocardial ischemia 1/157 (0.64%)   Hearing impaired 0/157 (0.00%)   Tinnitus 0/157 (0.00%)   Cataract 0/157 (0.00%)   Diplopia 0/157 (0.00%)   Glaucoma 0/157 (0.00%)   Vision blurred 0/157 (0.00%) Adverse Events 2:   Total: 14/157 (8.92%)   Blood disorder 0/157 (0.00%)   Hemoglobin decreased 2/157 (1.27%)   Hemolysis 1/157 (0.64%)   Arrhythmia 0/157 (0.00%)   Cardiac disorder 0/157 (0.00%)   Myocardial ischemia 0/157 (0.00%)   Hearing impaired 2/157 (1.27%)   Tinnitus 1/157 (0.64%)   Cataract 1/157 (0.64%)   Diplopia 0/157 (0.00%)   Glaucoma 1/157 (0.64%)   Vision blurred 1/157 (0.64%)
Secondary_evidence: Adverse Events 1:   Total: 6/168 (3.57%)   FEBRILE NEUTROPENIA 3/168 (1.79%)   ENTERITIS 1/168 (0.60%)   PERIPHERAL NEUROPATHY 2/168 (1.19%)   DEPRESSION 1/168 (0.60%)